Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis

Completed

• Conditions: Posterior Uveitis

• Registration Number: NCT03971279
• Lead Sponsor: Benha University

Brief Summary

VKH disease is a vision threatening condition.The investigators consider that ozurdex intravitreal implant is an effective line of treatment in recurrent VKH posterior uveitis.

Detailed Description

Baseline ,and postoperative 1 ,6 ,12 and 24 months full ophthalmic examination was done.

Procedure included intravitreal injection of Dexamethasone implant 0.7 mg (Ozurdex(®); Allergan, Inc, Irvine, CA)

Study Timeline

• Study Start: 2017-01-01
• Study First Submitted: 2019-05-30
• Study First Submitted QC: 2019-05-31
• Study First Posted: 2019-06-03
• Status Verified: 2019-11
• Primary Completion: 2019-11-22
• Study Completion: 2019-11-22
• Last Update Submitted: 2019-11-24
• Last Update Posted: 2019-11-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• Recurrent VKH posterior uveitis

Exclusion Criteria

• retinal pathology, other causes of posterior uveitis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Best corrected visual acuity (BCVA)	2 years	Change in BCVA

Secondary Outcome Measures

Name	Time	Method
optical coherence tomography (OCT) foveal thickness	2 years	changes in central foveal thickness

Trial Locations

Locations (1)

INMC; 🇦🇪 Abu Dhabi, United Arab Emirates